2022
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.
Shafi S, Aung T, Xirou V, Gavrielatou N, Vathiotis I, Fernandez A, Moutafi M, Yaghoobi V, Herbst R, Liu L, Langermann S, Rimm D. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. Laboratory Investigation 2022, 102: 1143-1149. PMID: 36775354, DOI: 10.1038/s41374-022-00796-6.Peer-Reviewed Original ResearchConceptsSiglec-15 expressionNon-small cell lung cancerNeck squamous cell carcinomaProgression-free survivalSquamous cell carcinomaCancer typesOverall survivalCell carcinomaBladder cancerImmune cellsSiglec-15PD-1/PD-L1 blockadePotential future clinical trialsQuantitative immunofluorescencePD-L1 blockadeStromal immune cellsImmune checkpoint blockadeCell lung cancerFuture clinical trialsNew potential targetsCheckpoint blockadePD-L1Lung cancerClinical trialsIntra-tumoral heterogeneityQuantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer
Shafi S, Aung TN, Xirou V, Gavrielatou N, Vathiotis IA, Fernandez A, Moutafi M, Yaghoobi V, Herbst RS, Liu LN, Langermann S, Rimm DL. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. Laboratory Investigation 2022, 102: 1143-1149. PMID: 35581307, PMCID: PMC10211373, DOI: 10.1038/s41374-022-00796-6.Peer-Reviewed Original ResearchConceptsSiglec-15 expressionNon-small cell lung cancerNeck squamous cell carcinomaProgression-free survivalSquamous cell carcinomaCancer typesOverall survivalCell carcinomaBladder cancerImmune cellsSiglec-15PD-1/PD-L1 blockadePotential future clinical trialsQuantitative immunofluorescencePD-L1 blockadeStromal immune cellsImmune checkpoint blockadeCell lung cancerFuture clinical trialsNew potential targetsCheckpoint blockadePD-L1Lung cancerClinical trialsIntra-tumoral heterogeneity
2021
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC
Hirsch FR, Redman MW, Moon J, Agustoni F, Herbst RS, Semrad TJ, Varella-Garcia M, Rivard CJ, Kelly K, Gandara DR, Mack PC. EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clinical Lung Cancer 2021, 23: 60-71. PMID: 34753703, PMCID: PMC8766941, DOI: 10.1016/j.cllc.2021.10.002.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaKRAS mutation statusAddition of cetuximabEGFR IHCMutation statusEGFR FISHAdvanced NSCLCSquamous cell lung cancerCetuximab-based therapyFirst-line chemotherapyPhase III trialsEGFR antibody therapyCell lung cancerImproved OSNon-SCCEGFR FISH statusEligible patientsOS benefitSCC patientsIII trialsKRAS statusCell carcinomaLung cancerSubgroup analysisExpression predicts
2020
A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clinical Lung Cancer 2020, 22: 170-177. PMID: 33221175, PMCID: PMC8044254, DOI: 10.1016/j.cllc.2020.09.013.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCohort StudiesFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPneumoniaProgression-Free SurvivalProto-Oncogene Proteins c-metSurvival RateTreatment OutcomeConceptsSquamous cell carcinomaProgression-free survivalTelisotuzumab vedotinCohort 1Recurrent squamous cell lung cancerSquamous cell lung cancerGrade 5 eventsMET-positive tumorsSolid Tumors v1.1Disease control ratePhase II studyResponse Evaluation CriteriaCell lung cancerDuration of responseLack of efficacyEvaluable patientsStable diseasePrimary endpointSecondary endpointsUnacceptable toxicityII studyOverall survivalCell carcinomaControl rateLung cancer
2017
Immune Checkpoint Inhibition in Lung Cancer
Morgensztern D, Herbst R. Immune Checkpoint Inhibition in Lung Cancer. 2017, 333-344. DOI: 10.1007/978-3-319-62431-0_20.Peer-Reviewed Original ResearchNon-small cell carcinomaSmall cell lung cancerLarge cell carcinomaSquamous cell carcinomaVascular endothelium growth factorLung cancerCell carcinomaEpidermal growth factor receptorMost patientsMetastatic non-small cell carcinomaPlatinum-based chemotherapy doubletsSmall molecule tyrosine kinase inhibitorsMolecule tyrosine kinase inhibitorsAbsence of contraindicationsImmune checkpoint inhibitionProlonged clinical benefitCell lung cancerStandard of careAmerican Cancer SocietyTyrosine kinase inhibitorsChemotherapy doubletsGrowth factor receptorNSCLC presentPalliative intentCheckpoint inhibitionOA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D
Herbst R, Redman M, Gandara D, Hirsch F, Mack P, Borghaei H, Langer C, Wade J, Engelman J, Edelman M, Albain K, Lara P, Aggarwal C, Socinski M, Gettinger S, Bazhenova L, Waqar S, Robert F, Kiefer G, Bradley J, Crawford J, Mcgary E, Rafique N, Petro D, Hoffman P, Zhou Y, Miao J, Griffin K, Mcdonough S, Miwa C, Malik S, Miller V, Sigal E, Adam S, Blanke C, Kelly K, Papadimitrakopoulou V. OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D. Journal Of Thoracic Oncology 2017, 12: s1783-s1784. DOI: 10.1016/j.jtho.2017.09.412.Peer-Reviewed Original ResearchMutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals Of Oncology 2017, 28: 83-89. PMID: 28177435, PMCID: PMC6246501, DOI: 10.1093/annonc/mdw437.Peer-Reviewed Original ResearchConceptsLung squamous cell carcinomaEarly stage lung squamous cell carcinomaNon-small cell lung cancerSquamous cell carcinomaWhole-exome sequencingImmune markersClinical outcomesCell carcinomaPIK3CA mutationsExact testPoor recurrence-free survivalProportional hazards regression modelsTumoral PD-L1 expressionPD-L1 expressionRecurrence-free survivalCell lung cancerComprehensive immune profilingTP53 mutant tumorsHazards regression modelsNormal lung tissuesFisher's exact testLUSC cohortAdjuvant therapyImmune profilingPoor prognosis
2015
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma
Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. Journal Of Clinical Investigation 2015, 126: 169-180. PMID: 26619122, PMCID: PMC4701554, DOI: 10.1172/jci82066.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, Squamous CellDasatinibDiscoidin Domain ReceptorsFemaleHead and Neck NeoplasmsHumansInositol 1,4,5-Trisphosphate ReceptorsLymphatic MetastasisMaleMiddle AgedMutationNeoplasm Recurrence, LocalReceptor Protein-Tyrosine KinasesReceptors, MitogenSquamous Cell Carcinoma of Head and NeckConceptsDiscoidin domain receptor tyrosine kinase 2Neck squamous cell carcinomaSquamous cell carcinomaRecurrent tumorsWhole-exome sequencingSynchronous lymphCell carcinomaPrimary tumorDDR2 mutationsTumor pairsSrc family kinase inhibitorRecurrent/metastatic HNSCCPrimary index tumorSynchronous nodal metastasesHalf of patientsReceptor tyrosine kinase 2Tyrosine kinase 2American Cancer SocietyIndex primary tumorPotential therapeutic targetPrecision medicine approachLong-term survivalRespective primary tumorsSomatic nucleotide variantsNational Cancer InstituteLung-MAP—framework, overview, and design principles
Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA. Lung-MAP—framework, overview, and design principles. Chinese Clinical Oncology 2015, 4: 36-36. PMID: 26408303, DOI: 10.3978/j.issn.2304-3865.2015.09.02.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaLung-MAPClinical trialsMetastatic lung squamous cell carcinomaLung squamous cell carcinomaLung SCC patientsLimited therapeutic optionsEvidence of efficacyPoor patient outcomesClinical trial designDriver genetic alterationsEligible patientsSCC patientsPatients' qualityTreatment armsTherapeutic optionsCell carcinomaTherapy clinical trialsPatient outcomesTrial designMaster protocolsPatientsFDA approvalGenomic profilingPromising agentInnovative Clinical Trials: The LUNG‐MAP Study
Steuer C, Papadimitrakopoulou V, Herbst R, Redman M, Hirsch F, Mack P, Ramalingam S, Gandara. Innovative Clinical Trials: The LUNG‐MAP Study. Clinical Pharmacology & Therapeutics 2015, 97: 488-491. PMID: 25676724, DOI: 10.1002/cpt.88.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicGenetic Predisposition to DiseaseGenomicsHumansLung NeoplasmsMolecular Targeted TherapyPhenotypePrecision MedicineResearch DesignSignal TransductionConceptsCell lung cancerSquamous cell carcinomaSquamous cell lung cancerCell carcinomaLung cancerTrial designNon-small cell lung cancerMetastatic squamous cell carcinomaSecond-line therapyProportion of patientsNew active drugsNovel trial designsDrug developmentWide molecular heterogeneityAdenocarcinoma histologyLine therapyTherapeutic optionsLung-MAPClinical trialsGroup trialsActive drugPatientsMaster protocolsCarcinomaCancerLung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clinical Cancer Research 2015, 21: 1514-1524. PMID: 25680375, PMCID: PMC4654466, DOI: 10.1158/1078-0432.ccr-13-3473.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaLung squamous cell carcinomaMaster protocolsClinical trialsAdvanced lung squamous cell carcinomaSquamous cell lung cancerCell lung cancerStandard of careMutation/amplificationTraditional clinical trialsDevelopment of therapiesInvestigational agentsCell carcinomaLung cancerCancer Genome Atlas (TCGA) projectMolecular abnormalitiesTherapyLungTrialsSignificant numberCarcinomaCancerAbnormalitiesProtocolCare
2012
Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx.
Acevedo-Gadea C, Baumgart M, Wang Z, Deshpande H, Davies M, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx. Journal Of Clinical Oncology 2012, 30: 5529-5529. DOI: 10.1200/jco.2012.30.15_suppl.5529.Peer-Reviewed Original ResearchSquamous cell carcinomaOP cancerOverall survivalHuman papillomavirusOral cavityAJCC stagePrognostic significanceCell carcinomaStage IFrequency of HPVNeck squamous cell carcinomaCurrent AJCC systemEnd Results registryKaplan-Meier methodEpidemiology of headL. PatientsPrognostic impactAJCC stagingOropharyngeal cancerPrognostic factorsStage IVBSurveillance EpidemiologyAJCC systemPatient populationClinical behaviorInfluence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck.
Baumgart M, Acevedo-Gadea C, Wang Z, Buta E, Davies M, Deshpande H, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2012, 30: 5532-5532. DOI: 10.1200/jco.2012.30.15_suppl.5532.Peer-Reviewed Original ResearchPoor prognostic factorSquamous cell carcinomaExtracapsular extensionOral cavityOverall survivalPrognostic factorsCell carcinomaIndependent poor prognostic factorNeck squamous cell carcinomaCox proportional hazards modelSignificant OS differenceSquamous cell cancerProportional hazards modelPrognostic impactSurveillance EpidemiologyCell cancerPoor outcomeKaplan-MeierECE statusOS differenceAJCC manualEligibility criteriaHazards modelPrimary siteSurvival curves
2009
Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck
William WN, Kim ES, Herbst RS. Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nature Reviews Clinical Oncology 2009, 6: 132-133. PMID: 19190590, DOI: 10.1038/ncponc1321.Peer-Reviewed Original ResearchAdvanced squamous cell carcinomaSquamous cell carcinomaCell carcinomaFirst phase III trialChemotherapy-alone armMedian overall survivalPrimary end pointPhase III trialsCetuximab armCetuximab therapyUntreated patientsIII trialsOverall survivalCurative treatmentCurable diseasePredictive markerSurvival advantageClinical practiceCetuximabPatientsEnd pointEXTREME trialTrialsChemotherapyCarcinoma
2008
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies
Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies. Cancer 2008, 112: 2710-2719. PMID: 18481809, DOI: 10.1002/cncr.23442.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Squamous CellCetuximabCisplatinClinical Trials as TopicDrug Resistance, NeoplasmHead and Neck NeoplasmsHumansMiddle AgedNeoplasm Recurrence, LocalProspective StudiesRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsMetastatic squamous cell carcinomaSquamous cell carcinomaMetastatic SCCHNPlatinum therapyRetrospective studyCell carcinomaEpidermal growth factor receptor (EGFR) inhibitor cetuximabActivity of cetuximabCarboplatin-based chemotherapyCetuximab-based treatmentCisplatin/carboplatinDisease control rateMedian overall survivalSecond-line therapySecond-line treatmentEfficacy of cetuximabPlatinum-based therapyOverall response ratePlatinum failureOverall survivalMedian timeProlong survivalProspective studyControl rateEfficacy data
2007
EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN)
Kies M, Ghebremichael M, Katz T, Herbst R, Youssoufian H, Burtness B. EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). Journal Of Clinical Oncology 2007, 25: 6024-6024. DOI: 10.1200/jco.2007.25.18_suppl.6024.Peer-Reviewed Original ResearchHigh EGFR expressionEGFR expressionRecurrent SCCHNTumor samplesCisplatin-based chemotherapySquamous cell carcinomaAssociation of responsePercentage of cellsHazard ratioProgressive diseaseCisplatin therapyPatient selectionCell carcinomaHigher eGFREGFR immunoreactivityInitial cohortCetuximabChemotherapyIndependent cohortFurther enrollmentPatientsSurvival analysisTumor resistanceDako kitSCCHN
2006
Therapeutic options to target angiogenesis in human malignancies
Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opinion On Emerging Drugs 2006, 11: 635-650. PMID: 17064223, DOI: 10.1517/14728214.11.4.635.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsHuman malignanciesMonoclonal antibodiesGrowth factorKinase inhibitorsAnti-VEGF inhibitorsGastrointestinal stromal tumorsSolid human malignanciesRenal cell carcinomaBasic fibroblast growth factorRole of VEGFTypes of cancerFibroblast growth factorStromal tumorsTherapeutic optionsCell carcinomaColorectal cancerAntiangiogenic drugsClinical trialsDrug classesPro-angiogenic growth factorsSmall molecule inhibitorsTumor growthTumor angiogenesisMatrix breakdown
2005
Tumor Cavitation in Stage I Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome
Onn A, Choe DH, Herbst RS, Correa AM, Munden RF, Truong MT, Vaporciyan AA, Isobe T, Gilcrease MZ, Marom EM. Tumor Cavitation in Stage I Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome. Radiology 2005, 237: 342-7. PMID: 16183941, DOI: 10.1148/radiol.2371041650.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellErbB ReceptorsFemaleFollow-Up StudiesHumansImmunohistochemistryLung NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisProportional Hazards ModelsRadiography, ThoracicReceptor, ErbB-2Retrospective StudiesSurvival RateTomography, X-Ray ComputedConceptsStage I non-small cell lung cancerNon-small cell lung cancerEpidermal growth factor receptorCell lung cancerSquamous cell carcinomaCavitary lesionsTumor diameterCell carcinomaLung cancerSurvival timePathologic stage I non-small cell lung cancerEGFR overexpressionProportional hazards regression modelsShorter disease-free survival timeShorter overall survival timeDisease-free survival timeEpidermal growth factor receptor expressionFindings of chestGrowth factor receptor expressionMedian overall survivalOverall survival timeHazards regression modelsPresence of calcificationFactor receptor expressionInstitutional review boardPhase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck
Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS. Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck. Journal Of Clinical Oncology 2005, 23: 5578-5587. PMID: 16009949, DOI: 10.1200/jco.2005.07.120.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellCetuximabCisplatinDisease ProgressionDrug Administration ScheduleFemaleFluorouracilHead and Neck NeoplasmsHumansLogistic ModelsMaleMiddle AgedNeoplasm Recurrence, LocalPaclitaxelSurvival AnalysisTreatment OutcomeConceptsSquamous cell carcinomaSkin rashCell carcinomaAcne-like skin rashMulticenter phase II studyPhase II multicenter studyRefractory squamous cell carcinomaMedian overall survival timeEpidermal growth factor receptor antibody cetuximabRecurrent squamous cell carcinomaCisplatin/fluorouracilCisplatin/paclitaxelSafety of cetuximabPhase II studyMajority of patientsOverall survival timePlatinum-based therapySingle-agent trialsSerious allergic reactionsMurine monoclonal antibodiesActive regimenStable diseaseCommon toxicitiesII studyMedian duration
2004
Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer
Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O’Reilly M, Hong WK, Fidler IJ, Putnam JB, Herbst RS. Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer. Clinical Cancer Research 2004, 10: 136-143. PMID: 14734462, DOI: 10.1158/1078-0432.ccr-0373-3.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, Bronchiolo-AlveolarAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDisease ProgressionErbB ReceptorsFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLung NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPhosphorylationPrognosisReceptor, ErbB-2Retrospective StudiesRisk FactorsSurvival RateTransforming Growth Factor alphaConceptsStage I non-small cell lung cancerNon-small cell lung cancerEpidermal growth factor receptorCell lung cancerSquamous cell carcinomaHER2-neuGrowth factor alphaPhosphorylated epidermal growth factor receptorGrowth factor receptorCell carcinomaLung cancerFactor alphaPathological stage I non-small cell lung cancerFactor receptorPotential prognostic factorsShorter overall survivalPatients' clinical outcomesSynchronous overexpressionHER2-neu overexpressionLung cancer progressionMaximal therapyMetastatic diseaseOverall survivalPrognostic factorsClinical outcomes